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Abstract
The principle of pragmatism in clinical trials has been broadly recognised as a way to close the
gap between research and practice. In this contribution, we argue that the conduct of prag-
matic clinical trials in Europe may be hampered by poor implementation of current
European Union’s Clinical Trial Regulation No. 536/2014.
Introduction
In recent years, the value of pragmatism in clinical trials has been strongly emphasised.
Pragmatic trials aim to assess interventions under real-life circumstances by (a) recruiting par-
ticipants similar to those who would receive the intervention in ordinary care; (b) involving
unselected health care facilities; (c) comparing novel interventions with current standards of
care; and (d) employing clinically relevant outcomes (Ford and Norrie, 2016). However, as prag-
matic designs should resemble clinical practice as much as possible, they might conflict with
technical and administrative procedures required by the European Union (EU) for the conduct
of experimental studies, including pharmacovigilance procedures. In particular, local imple-
mentation of Directive 2001/20/EC, originally ‘[…] aimed at harmonizing clinical trial proce-
dures and improving collaboration among EU member states […]’, raised a number of
administrative and economic issues (The European Parliament and the Council of the
European Union, 2001). Consequently, applications for clinical trials in the EU progressively
decreased (European Commission, 2012), until a new regulation, called Clinical Trial
Regulation No. 536/2014, was issued (The European Parliament and the Council of the
European Union, 2014). Novel aspects of this regulation include harmonised electronic submis-
sion and assessment processes between EU member states; faster and centralised submission
and assessment of trials’ protocols; improved information sharing and decision making between
and within EU member states; economic facilitations (e.g. concept of co-sponsorship); highest
safety standards for patients; increased transparency of information on clinical trials (Gokhale
and Berry, 2018; Tenti et al., 2018; Scavone et al., 2019). Proper implementation of this new
regulation remains a challenging process, which actively involves national and local authorities,
who are supposed to remove out-to-date, country-specific requirements for the conduction of
clinical trials (Gokhale and Berry, 2018). Legislative discrepancies among EU member states
is postponing the full implementation of this regulation, although clear data on the situation
in each European country are not available (Scavone et al., 2019).
In this contribution we argue that poor implementation of the EU regulation is a major
barrier towards the development and conduct of pragmatic trials in Europe. We briefly
describe a pragmatic clinical trial on antidepressants currently ongoing in Italy, as this repre-
sents a case-example of the practical consequences of a lacking implementation of the last EU
regulation.
The VESPA study
The VESPA study (Vortioxetine in the Elderly v. SSRIs: a Pragmatic Assessment) is a rando-
mised, open-label, phase IV, multicentre study, involving 13 centres in Italy. The study, finan-
cially supported by the Italian Medicine Agency, is currently ongoing, and its protocol is
publicly available (ClinicalTrials.gov Identifier: NCT03779789). According to a pragmatic
approach, the study will (a) recruit elderly participants with broad inclusion criteria in real-
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world settings (including both out- and in-patient settings); (b)
randomise participants to vortioxetine or one of the selective sero-
tonin reuptake inhibitors (SSRIs) (including sertraline, citalo-
pram, escitalopram, fluoxetine, fluvoxamine, paroxetine),
allowing clinicians to choose which SSRI better adapts to each
individual participant; and (c) allow the same doctors to simul-
taneously collect socio-demographic and clinical data, randomise,
and prescribe the antidepressant within a reasonable timeframe.
Concerns about pragmatism
As a result of poor implementation of the EU Clinical Trial
Regulation No. 536/2014 in Italy requirements of the previous
regulation are still in place and need to be followed.
Consequently, participants involved in clinical trials cannot sim-
ply get the prescribed medicines at any local community phar-
macy, as they would usually do outside an experimental design
and as recommended by the new EU regulation (No. 536/214).
On the contrary, in experimental settings in Italy, they must
receive medicine boxes re-labelled by the pharmacy of the health
care facility where the enrolment takes place. Information
reported in this additional label (EudraCT code of the study;
patient’s unique code; name and phone number of the study pro-
moter) is intended to enhance a transparent, easily verifiable and
traceable system for the experimental medicines (The European
Parliament and the Council of the European Union, 2010). We
note that this procedure is associated with at least two feasibility
issues that inevitably affect pragmatism.
First, having drugs provided just by the pharmacy of the enrol-
ment site’s health care facility consequently reduces the possibility
to prescribe medicines to a smaller range, as compared to what is
available in the market, as health care facility pharmacies have
their own pharmaceutical formularies, which usually include
only a selection of medicines available in the community
(Bjorkhem-Bergman et al., 2013). In the case of the VESPA
study, vortioxetine, although currently marketed in Italy and avail-
able in community pharmacies, is not yet available in most health
care facility pharmacies. As a consequence, in order to prescribe
vortioxetine to participants, additional study funding is needed
to purchase it, although in ordinary practice it would be refunded
by the National Health System. Furthermore, as health care facility
pharmacies usually have only a selection of the SSRIs available, and
this selection might differ according to the recruiting centre, the
doctor’s choice is relevantly limited and much different from
usual care, with also a risk of unbalances between centres having
different SSRI selections. These limitations, related to regulatory
requirements, deeply alter ordinary practice, and are hardly com-
patible with the original design of the study.
Second, referring the included patients to the health care facility
pharmacies, rather than to the local community pharmacies, carries
practical issues. Health care facility pharmacies have limited open-
ing hours, which might be a problem both for younger working
patients and for elderly participants, particularly those with limited
autonomyandneeding continuous care. Also, considering the com-
plex therapeutic regimens of most of these patients, they (and their
caregivers) might find difficult to collect different medicines at dif-
ferent pharmacies. In order to overcome this challenge, investiga-
tors may directly provide re-labelled medicines to the study
participants. Although this would ease participants’ routine, it
still carries practical and methodological limitations. Doctors
involved in the recruitment will need a stock of re-labelledmedicine
boxes in their visiting rooms, and this requires time-consuming
procedures to ensure security and regular re-supply. Also, for doc-
tors recruiting patients admitted to medical wards it might be diffi-
cult to carry around a whole stock of medication boxes. Moreover,
directly providing medicine boxes to participants is likely to affect
treatment adherence as compared to everyday practice, where issu-
ing a prescription does not guarantee acquisition and consumption
(Blaschke et al., 2012).
The above-described scenarios represent significant departures
from everyday clinical practice, making the recruitment process
demanding for both investigators and participants, and pro-
foundly affecting pragmatism. Of notice, this might discourage
doctors from community-based non-academic services to take
part in the study. The pragmatic value of routinely involving non-
academic professionals in clinical trials has been highlighted
(Rahman et al., 2011), as they represent the best access point to
real-world practice. Figure 1 shows the original level of pragma-
tism of the VESPA study according to the PRECIS-2 tool
(Loudon et al., 2015), and how it is decreased in four different
Fig. 1. Changes in PRECIS-2 scores after applying EU regula-
tions on pharmacovigilance (higher scores indicate higher
levels of pragmatism).
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areas (namely flexibility adherence, flexibility delivery, organisa-
tion and setting) as a consequence of the current implementation
of EU regulations in Italy.
Future perspectives
The EU Clinical Trial Regulation No. 536/2014 states that ‘Where
the investigational or auxiliary medicinal product have already been
placed on the market […], as a general rule no additional labelling
should be required for clinical trials that do not involve the blinding
of the label’. This simple statement should allow phase IV clinical
trials to undergo the same level of pharmacovigilance monitoring
applied to ordinary practice. However, the example-case described
here shows how this regulation still waits to be properly implemen-
ted in Italy. Arguably, similar concerns are to be extended to many
other EU state members, although clear data are lacking (Scavone
et al., 2019). Going further, considering that (a) the level of mon-
itoring in clinical trials is higher compared with clinical practice,
and (b) pragmatism enhances the generalisability of study results
to real-world populations, one might even argue that highly prag-
matic studies represent the best possible source of data for effective
pharmacovigilance.
In conclusion, efforts by national (such as the Italian
Medicines Agency) and local authorities are urgently required
to fully implement the Clinical Trial Regulation No. 536/2014,
not only to harmonise trials’ procedures, reduce costs, and
increase transparency and safety standards, but also to support
the conduction of more pragmatic phase IV trials, which
represent a seminal step towards data easily generalisable to real-
world practice, and, ultimately, better standards of care.
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